Information Provided By: 
Fly News Breaks for April 24, 2015
REGN
Apr 24, 2015 | 06:43 EDT
Leerink analyst Joseph Schwartz raised his price target for shares of Regeneron to $527 from $425 while reiterating an Outperform rating on the name. The target raise is the result of Schwartz increasing his probability of success and sarcopenia market opportunity for REGN1033 to 33% and $4.75B, respectively. Regeneron reported yesterday the drug met its primary endpoint goal in a Phase 1 study. Regeneron shares closed Thursday up $7.45 to $480.08.
News For REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
